Intensity Therapeutics posts Q2 2025 corporate presentation; no new material data disclosed

INTENSITY THERAPEUTICS, INC.

Presentation references lead candidate INT230-6 and DfuseRx platform for solid tumor treatment.
No specific clinical results, financial updates, or guidance changes are included in the filed excerpt.
Document furnished under Regulation FD; not deemed filed for SEC liability purposes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.